SCNI News
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireJERUSALEM, Sept. 21, 2026 Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above...
PR Newswire
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireJERUSALEM, Sept. 21, 2026 Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above...
PR Newswire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers
Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session.
Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The company'sread more...
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers
Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million.
Definium Therapeutics (NASDAQ:DFTX)read more...
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million.
Corbus Pharmaceuticalsread more...
Benzinga
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business PR Newswire JERUSALEM, Sept. 8, 2026 Following the conclusion of the PinCell option and...
PR Newswire
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum PR Newswire JERUSALEM, Aug. 24, 2026 Investor webinar scheduled for August 26, 2026 at...
PR Newswire
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration PR Newswire JERUSALEM, Aug. 10, 2026...
PR Newswire
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and...
PR Newswire
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility PR Newswire JERUSALEM, May 20, 2026 JERUSALEM, May 20, 2026 /PRNewswire/ Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai...
PR Newswire
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe Scinai Immunotherapeutics to Lead...
PR Newswire